LitAlert ~~ GeneLit.com

    • Contralateral risk-reducing local therapy in breast cancer patients with BRCA1/2 mutations: systemic review and meta-analysis.
    • Jia Z, Li J, Zhang Y, Wang X, Xing J, Xing Z, Huang X, Liu G, Zhang M, Feng K, Wu J, Wang W, Wang J, Liu J, Wang X.
    • Cancer Cell Int. 2021 Sep 25;21(1):512. doi: 10.1186/s12935-021-02194-2.
    • Tackling PARP inhibitor resistance.
    • Fugger K, Hewitt G, West SC, Boulton SJ.
    • Trends Cancer. 2021 Sep 22:S2405-8033(21)00175-8. doi: 10.1016/j.trecan.2021.08.007. Epub ahead of print.
    • Review
    • The role of the tumor primary chemosensitivity relative to the success of the medical-surgical management in patients with advanced ovarian carcinomas.
    • You B, Freyer G, Gonzalez-Martin A, Lheureux S, McNeish I, Penson RT, Pignata S, Pujade-Lauraine E.
    • Cancer Treat Rev. 2021 Sep 15;100:102294. doi: 10.1016/j.ctrv.2021.102294. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Active Targeted Nanoparticles for Delivery of Poly(ADP-ribose) Polymerase (PARP) Inhibitors: A Preliminary Review.
    • Sargazi S, Mukhtar M, Rahdar A, Barani M, Pandey S, Díez-Pascual AM.
    • Int J Mol Sci. 2021 Sep 25;22(19):10319. doi: 10.3390/ijms221910319.
    • Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation – real life data.
    • Ataseven B, Tripon D, Schwameis R, Harter P, Rhiem K, Schneider S, Heikaus S, Baert T, Francesco APHeitz F, Traut A, Groeben HT, Schmutzler R, du Bois A.
    • Gynecol Oncol. 2021 Sep 23:S0090-8258(21)01335-4. doi: 10.1016/j.ygyno.2021.09.004. Epub ahead of print.
    • Oncoplastic Mammoplasty with disguised geometric compensation.
    • Paulinelli RR, Ribeiro LFJ, Santos TD, Caires EMS, Pontes MGM, Faria BM, Luz MV, Faria SFC, Freitas-Junior R.
    • Surg Oncol. 2021 Sep 20;39:101660. doi: 10.1016/j.suronc.2021.101660. Epub ahead of print.
    • Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    • Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, Andújar-Sánchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J.
    • Mol Cell. 2021 Sep 18:S1097-2765(21)00739-5. doi: 10.1016/j.molcel.2021.09.005. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Management of breast cancer patients with BRCA gene mutations in Lebanon of the Middle East: perspectives and challenges.
    • El Saghir NS, Ghanem H, El Karak F, Farhat F, Ghosn M, Makdessi J, Chouaib K, Debs J, Tabchy AB.
    • Hosp Pract (1995). 2021 Sep 22:1-5. doi: 10.1080/21548331.2021.1974678. Epub ahead of print.
    • Commentary
    • Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
    • Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Amenedo Gancedo M, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Cameron T, Maloney L, Goble S, Ledermann JA, Coleman RL.
    • Cancer Med. 2021 Sep 21. doi: 10.1002/cam4.4260. Epub ahead of print.
    • Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    • Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim T, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer L, Sun C, Sood AK, Coleman RL, Mills GB.
    • Clin Cancer Res. 2021 Sep 13. doi: 10.1158/1078-0432.CCR-21-1656. Epub ahead of print.
  • LitAlert ~~ GeneLit.com

    • Next-Generation Sequencing-Directed Therapy in Patients with Metastatic Breast Cancer in Routine Clinical Practice.
    • Bruzas S, Kuemmel S, Harrach H, Breit E, Ataseven B, Traut A, Rüland A, Kostara A, Chiari O, Dittmer-Grabowski C, Reinisch M.
    • Cancers (Basel). 2021 Sep 11;13(18):4564. doi: 10.3390/cancers13184564.
    • Inside prostate cancer news from the 2021 ASCO Genitourinary Cancers Symposium.
    • Iacovelli R, Astore S, Ciccarese C, Cannella MA, Bove P, Iacovelli V, Tortora G.
    • Expert Rev Anticancer Ther. 2021 Sep 9:1-4. doi: 10.1080/14737140.2021.1976148. Epub ahead of print.
    • Conference report
    • Adherence to PARP inhibitor therapy among women with ovarian cancer.
    • Moss HA, Chen L, Hershman DL, Davidson B, Wright JD.
    • Gynecol Oncol. 2021 Sep 9:S0090-8258(21)01323-8. doi: 10.1016/j.ygyno.2021.08.025. Epub ahead of print.
    • Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.
    • Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C.
    • Immunotherapy. 2021 Sep 8. doi: 10.2217/imt-2021-0024. Epub ahead of print.
    • Review
    • REV1-Pol? maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps.
    • Taglialatela A, Leuzzi G, Sannino V, Cuella-Martin R, Huang JW, Wu-Baer F, Baer R, Costanzo V, Ciccia A.
    • Mol Cell. 2021 Sep 7:S1097-2765(21)00683-3. doi: 10.1016/j.molcel.2021.08.016. Epub ahead of print.
    • Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    • Hodgson D, Lai Z, Dearden S, Barrett JC, Harrington EA, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek SM, Robson M.
    • Ann Oncol. 2021 Sep 6:S0923-7534(21)04458-6. doi: 10.1016/j.annonc.2021.08.2154. Epub ahead of print.
    • Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
    • Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, Beutel AK, Gout J, Stenzinger A, Van Cutsem E, Bellmunt J, Hammel P, O'Reilly EM, Seufferlein T.
    • Cancers (Basel). 2021 Aug 24;13(17):4259. doi: 10.3390/cancers13174259.
  • LitAlert ~~ GeneLit.com

    • Immune checkpoint inhibitor sensitivity of DNA repair deficient tumors.
    • Rochefort P, Desseigne F, Bonadona V, Dussart S, Coutzac C, Sarabi M, la Fouchardiere C.
    • Immunotherapy. 2021 Sep 8. doi: 10.2217/imt-2021-0024. Epub ahead of print.
    • Review
    • Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
    • Mahdi H, Hafez N, Doroshow D, Sohal D, Keedy V, Do KT, LoRusso P, Jürgensmeier J, Avedissian M, Sklar J, Glover C, Felicetti B, Dean E, Mortimer P, Shapiro GI, Eder JP.
    • JCO Precis Oncol. 2021;5:1432. doi: 10.1200/PO.20.00439. Epub 2021 Sep 7.
    • Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases.
    • Gallego A, Garrido D, Yébenes L, Mendiola M, Castelo B, Redondo A.
    • Int J Gynecol Cancer. 2021 Sep;31(9):1292-1296. doi: 10.1136/ijgc-2020-002225.
    • The Fanconi anemia pathway and Breast Cancer: A comprehensive review of clinical data.
    • Gianni P, Matenoglou E, Geropoulos G, Agrawal N, Adnani H, Zafeiropoulos S, Miyara SJ, Guevara S, Mumford JM, Molmenti EP, Giannis D.
    • Clin Breast Cancer. 2021 Aug 10:S1526-8209(21)00238-X. doi: 10.1016/j.clbc.2021.08.001. Epub ahead of print.
    • Review
  • LitAlert ~~ GeneLit.com

    • Germline variants in DNA repair genes, including BRCA1/2, may cause familial myeloproliferative neoplasms.
    • Elbracht M, Meyer R, Kricheldorf K, Gezer D, Thomas E, Betz B, Kurth I, Teichmann LL, Brümmendorf TH, Germing U, Isfort S, Koschmieder S.
    • Blood Adv. 2021 Sep 14;5(17):3373-3376. doi: 10.1182/bloodadvances.2021004811.
    • Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy.
    • Matsuo K, Klar M, Mohrbacher AF, Roman LD, Wright JD.
    • Eur J Cancer. 2021 Sep 3;157:P59-62. doi: 10.1016/j.ejca.2021.08.016. Epub ahead of print.
    • Letter
    • Unusual metastasis in BRCA mutated pancreatic cancer while on maintenance Olaparib: Two case reports and review of the literature.
    • Assaf I, Mans L, Sakr R, Verset G, Van Laethem JL.
    • Eur J Cancer. 2021 Sep 3;157:P63-67. doi: 10.1016/j.ejca.2021.07.042. Epub ahead of print.
    • Case report
    • Patients with bi-allelic BRCA1/2 inactivation respond to olaparib treatment across histologic tumor types.
    • van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW.
    • Clin Cancer Res. 2021 Sep 2:clincanres.1104.2021. doi: 10.1158/1078-0432.CCR-21-1104. Epub ahead of print.
    • Hereditary pancreatic cancer.
    • Abe K, Kitago M, Kitagawa Y, Hirasawa A.
    • Int J Clin Oncol. 2021 Sep 2. doi: 10.1007/s10147-021-02015-6. Epub ahead of print.
    • Genetic testing in patients with triple-negative or hereditary breast cancer.
    • Bernstein-Molho R, Evron E, Yerushalmi R, Paluch-Shimon S.
    • Curr Opin Oncol. 2021 Sep 1. doi: 10.1097/CCO.0000000000000784. Epub ahead of print.
    • Review
    • Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications.
    • Moretto R, Elliott A, Zhang J, Arai H, Germani MM, Conca V, Xiu J, Stafford P, Oberley M, Abraham J, Spetzler D, Rossini D, Antoniotti C, Marshall J, Shields A, Lopes G, Lonardi S, Pietrantonio F, Tomasello G, Passardi A, Tamburini E, Santini D, Aprile G, Masi G, Falcone A, Lenz HJ, Korn M, Cremolini C.
    • J Natl Cancer Inst. 2021 Sep 1:djab169. doi: 10.1093/jnci/djab169. Epub ahead of print.

    Research news:

    Are Homologous Recombination Deficiency Mutations Relevant in Colorectal Cancer?

    • Ovarian Serous Carcinoma With a Novel HSP90AB1 Mutation in a Patient With Synchronous Primary Fallopian Tube Serous Carcinoma.
    • Lai J, Tong C, Chien JR.
    • Anticancer Res. 2021 Sep;41(9):4417-4422. doi: 10.21873/anticanres.15248.
    • Case report
    • A rare case of breast cancer in a transgender woman.
    • Sieberg R, Soriano K, Zuurbier R.
    • Radiol Case Rep. 2021 Aug 26;16(11):3285-3288. doi: 10.1016/j.radcr.2021.07.052.
  • LitAlert ~~ GeneLit.com

    • Pioneering BRCA1/2 point-of-care testing for integration of germline and tumor genetics in breast cancer risk management: A vision for the future of translational pharmacogenomics.
    • Mampunye L, Van Der Merwe NC, Grant KA, Peeters AV, Sawe RT, French D, Moremi K, Kidd M, van Eeden PC, Pienaar FM, Kotze MJ.
    • Front Oncol. 2021 Aug 31;10:619817. doi: 10.3389/fonc.2021.619817.
    • Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
    • Aziz D, Portman N, Fernandez KJ, Lee C, Alexandrou A, Llop-Guevara A, Phan Z, Yong A, Wilkinson A, Sergio CM, Ferraro D, Etemadmoghadam D, Bowtell DD, kConFab Investigators, Serra V, Waring P, Lim E, Caldon CE.
    • NPJ Breast Cancer. 2021 Aug 31;7(1):111. doi: 10.1038/s41523-021-00312-x.
    • G-quadruplex DNA: a novel target for drug design.
    • Teng FY, Jiang ZZ, Guo M, Tan XZ, Chen F, Xi XG, Xu Y.
    • Cell Mol Life Sci. 2021 Aug 30. doi: 10.1007/s00018-021-03921-8. Epub ahead of print.
    • Review